These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 24525810

  • 1. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
    Crawford AA, Lewis S, Nutt D, Peters TJ, Cowen P, O'Donovan MC, Wiles N, Lewis G.
    Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810
    [Abstract] [Full Text] [Related]

  • 2. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K, Yassouridis A, Kellner M, Jahn H, Wiedemann K, Raedler TJ.
    J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
    [Abstract] [Full Text] [Related]

  • 3. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M, Lewis G, Nutt DJ, Peters TJ, Wiles NJ, Lewis G.
    J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
    [Abstract] [Full Text] [Related]

  • 4. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
    Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G.
    Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
    [Abstract] [Full Text] [Related]

  • 5. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M.
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
    [Abstract] [Full Text] [Related]

  • 6. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
    Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM.
    J Affect Disord; 2009 Nov; 118(1-3):87-93. PubMed ID: 19250683
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E, Demir EY, Cosar B.
    Adv Ther; 2006 Nov; 23(6):974-87. PubMed ID: 17276965
    [Abstract] [Full Text] [Related]

  • 8. 5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test.
    Günther L, Rothe J, Rex A, Voigt JP, Millan MJ, Fink H, Bert B.
    Neuropharmacology; 2011 Sep; 61(3):433-41. PubMed ID: 21419787
    [Abstract] [Full Text] [Related]

  • 9. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [Abstract] [Full Text] [Related]

  • 10. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 11. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.
    Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Peters TJ.
    Br J Psychiatry; 2011 Jun; 198(6):464-71. PubMed ID: 21263010
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression.
    Hegerl U, Mergl R, Henkel V, Pogarell O, Müller-Siecheneder F, Frodl T, Juckel G.
    Psychopharmacology (Berl); 2005 Feb; 178(1):58-66. PubMed ID: 15316714
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Depersonalization-derealization syndrome induced by reboxetine.
    Khazaal Y, Zullino DF.
    Swiss Med Wkly; 2003 Jul 12; 133(27-28):398-9. PubMed ID: 12947529
    [Abstract] [Full Text] [Related]

  • 16. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O, Hetzel G, Michael N, Rothermundt M, Arolt V, Erfurth A.
    Neuropsychobiology; 2005 Jul 12; 51(2):67-71. PubMed ID: 15741746
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H, Van Moffaert M, Gagiano CA.
    Eur Neuropsychopharmacol; 1997 Apr 12; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [Abstract] [Full Text] [Related]

  • 18. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
    Bould H, Wiles N, Potokar J, Cowen P, Nutt DJ, Peters TJ, Lewis G.
    J Psychopharmacol; 2012 May 12; 26(5):663-9. PubMed ID: 22223618
    [Abstract] [Full Text] [Related]

  • 19. [Reboxetine (Edronax)].
    Souery D, Sternon J.
    Rev Med Brux; 1999 Dec 12; 20(6):511-6. PubMed ID: 10672775
    [Abstract] [Full Text] [Related]

  • 20. A review of the adverse effects and safety of noradrenergic antidepressants.
    Whiskey E, Taylor D.
    J Psychopharmacol; 2013 Aug 12; 27(8):732-9. PubMed ID: 23784737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.